Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Review, H1 2016', provides in depth analysis on Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted pipeline therapeutics. The report provides comprehensive information on the Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - The report reviews Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects - The report assesses Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD (+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) Overview 10 Therapeutics Development 11 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Stage of Development 11 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Therapy Area 12 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Indication 13 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Companies 17 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Products under Development by Universities/Institutes 23 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Therapeutics Assessment 25 Assessment by Monotherapy/Combination Products 25 Assessment by Mechanism of Action 26 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development 31 AbbVie Inc. 31 American Gene Technologies International Inc. 32 AstraZeneca Plc 33 BeiGene, Ltd. 34 Clovis Oncology, Inc. 35 Eisai Co., Ltd. 36 Hager Biosciences, LLC 37 IMPACT Therapeutics, Inc. 38 Jeil Pharmaceutical Co., Ltd. 39 Jiangsu Hengrui Medicine Co., Ltd. 40 Mitsubishi Tanabe Pharma Corporation 41 Nerviano Medical Sciences S.r.l. 42 Takeda Pharmaceutical Company Limited 43 Tesaro, Inc. 44 Teva Pharmaceutical Industries Ltd. 45 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Drug Profiles 46 ABT-767 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 AGPD - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AZ-0108 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 BGB-290 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 CK-102 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 E-7449 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 fluzoparib - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 IMP-04297 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 JPI-289 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 MP-124 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 niraparib - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 NMSP-118 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 NMSP-648 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 NMSP-914 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 olaparib - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 R-503 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 rucaparib phosphate - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Small Molecule to Inhibit PARP-1 for Undisclosed Indication - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Small Molecules to Inhibit PARP-1 for Colon Cancer - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 veliparib - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 XZ-120312 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 YHP-743 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Dormant Projects 93 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Discontinued Products 99 Poly (ADP-Ribose) Polymerase 1 (ADP-Ribosyltransferase Diphtheria Toxin-Like 1 or PARP-1 or NAD(+) ADP-Ribosyltransferase 1 or ADPRT 1 or Poly[ADP-Ribose] Synthase 1 or EC 2.4.2.30) - Featured News & Press Releases 100 Jun 06, 2016: Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting 100 Jun 05, 2016: LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer 103 Jun 04, 2016: TESARO Provides Update on niraparib at ASCO Investor Briefing 105 Jun 04, 2016: Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation 105 May 19, 2016: Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting 106 May 18, 2016: TESARO Announces Three Abstracts on Niraparib to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting 107 May 18, 2016: AstraZeneca provides top-line results from Lynparza GOLD trial in advanced gastric cancer 108 May 18, 2016: AbbVie To Present Data on Veliparib at at ASCO 2016 109 Apr 27, 2016: Lynparzatm (Olaparib) Now Available To NHS Patients In England And Wales With BRCA-Mutated Ovarian Cancer 109 Apr 18, 2016: AstraZeneca Presents New Data On PARP Inhibitor Lynparza (olaparib) at the AACR 2016 Annual Meeting 110 Apr 14, 2016: Myriad Genetics announces presentation on niraparib study at the 2016 American Association for Cancer Research Annual Meeting 111 Jan 28, 2016: Lynparza (olaparib) granted Breakthrough Therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer 111 Jan 27, 2016: NICE recommends olaparib for ovarian cancer 112 Jan 25, 2016: Clovis Oncology Names Dale Hooks as Chief Commercial Officer, Provides Update On Rucaparib 112 Dec 11, 2015: NICE intends to recommend olaparib for ovarian, fallopian tube and peritoneal cancer after company provides more information 113 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Development by Companies, H1 2016 (Contd..2) 20 Products under Development by Companies, H1 2016 (Contd..3) 21 Products under Development by Companies, H1 2016 (Contd..4) 22 Number of Products under Investigation by Universities/Institutes, H1 2016 23 Products under Investigation by Universities/Institutes, H1 2016 24 Assessment by Monotherapy/Combination Products, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 26 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Pipeline by AbbVie Inc., H1 2016 31 Pipeline by American Gene Technologies International Inc., H1 2016 32 Pipeline by AstraZeneca Plc, H1 2016 33 Pipeline by BeiGene, Ltd., H1 2016 34 Pipeline by Clovis Oncology, Inc., H1 2016 35 Pipeline by Eisai Co., Ltd., H1 2016 36 Pipeline by Hager Biosciences, LLC, H1 2016 37 Pipeline by IMPACT Therapeutics, Inc., H1 2016 38 Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 39 Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 40 Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 41 Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 42 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 43 Pipeline by Tesaro, Inc., H1 2016 44 Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 45 Dormant Projects, H1 2016 93 Dormant Projects (Contd..1), H1 2016 94 Dormant Projects (Contd..2), H1 2016 95 Dormant Projects (Contd..3), H1 2016 96 Dormant Projects (Contd..4), H1 2016 97 Dormant Projects (Contd..5), H1 2016 98 Discontinued Products, H1 2016 99
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
